|
1
|
De Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.
|
|
2
|
Goldberg RM, Sargent DJ, Morton RF, et al:
A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar
|
|
3
|
Rothenberg ML, Oza AM, Bigelow RH, et al:
Superiority of oxaliplatin and fluorouracil-leucovorin compared
with either therapy alone in patients with progressive colorectal
cancer after irinotecan and fluorouracil-leucovorin: interim
results of a phase III trial. J Clin Oncol. 21:2059–2069. 2003.
View Article : Google Scholar
|
|
4
|
Douillard JY, Cunningham D, Roth AD, et
al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tournigand C, André T, Achille E, et al:
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: a randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hochster HS, Hart LL, Ramanathan RK, et
al: Safety and efficacy of oxaliplatin and fluoropyrimidine
regimens with or without bevacizumab as first-line treatment of
metastatic colorectal cancer: results of the TREE Study. J Clin
Oncol. 21:3523–3529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saltz LB, Clarke S, Díaz-Rubio E, et al:
Bevacizumab in combination with oxaliplatin-based chemotherapy as
first-line therapy in metastatic colorectal cancer: a randomized
phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giantonio BJ, Catalano PJ, Meropol NJ, et
al: Bevacizumab in combination with oxaliplatin, fluorouracil, and
leucovorin (FOLFOX4) for previously treated metastatic colorectal
cancer: results from the Eastern Cooperative Oncology Group Study
E3200. J Clin Oncol. 25:1539–4154. 2007. View Article : Google Scholar
|
|
9
|
Bokemeyer C, Bondarenko I, Makhson A, et
al: Fluorouracil, leucovorin, and oxaliplatin with and without
cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maughan TS, Adams R, Smith CG, et al:
Identification of potentially responsive subsets when cetuximab is
added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in
first-line advanced colorectal cancer (aCRC). J Clin Oncol.
28(Suppl 5): abs. 3502. 2010.
|
|
11
|
Fuchs CS, Marshall J, Mitchell E, et al:
Randomized, controlled trial of irinotecan plus infusional, bolus,
or oral fluoropyri-midines in first-line treatment of metastatic
colorectal cancer: results from the BICC-C Study. J Clin Oncol.
25:4779–4786. 2007. View Article : Google Scholar
|
|
12
|
Van Cutsem E, Köhne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Eng J Med. 360:1408–1417. 2009.PubMed/NCBI
|
|
13
|
Winder T and Lenz HJ: Molecular predictive
and prognostic marker in colon cancer. Cancer Treat Rev.
36:550–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ochiai T, Nishimura K, Noguchi H, Kitajima
M, Tsuruoka Y and Takahashi Y: Evaluation of 5-fluorouracil
applicability by multi-point collagen gel droplet embedded drug
sensitivity test. Oncol Rep. 14:201–205. 2005.PubMed/NCBI
|
|
15
|
Ochiai T, Nishimura K, Noguchi H, et al:
Evaluation of 5-fluorouracil applicability by the collagen gel
droplet embedded drug sensitivity test with area under the curve
analysis. Anticancer Drugs. 18:17–21. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kobayashi H, Higashiyama M, Minamigawa K,
et al: Examination of in vitro chemosensitivity test using collagen
gel droplet culture method with colorimetric endpoint
quantification. Jpn J Cancer Res. 92:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gill S, Loprinzi CL, Sargent DJ, et al:
Pooled analysis of fluorouracil-based adjuvant therapy for stage II
and III colon cancer: who benefits and by how much? J Clin Oncol.
22:1797–1806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ochiai T, Nishimura K, Watanabe T, et al:
Evaluation of the individual 50% inhibitory area under the
concentration curve of 5-fluorouracil based on the collagen gel
droplet embedded culture drug sensitivity test in colorectal
cancer. Mol Med Rep. 2:405–409. 2009.
|
|
19
|
André T, Boni C, Mounedji-Boudiaf L, et
al: Multicenter international study of
oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of
colon cancer (MOSAIC) investigators. N Eng J Med. 350:2343–2351.
2004.
|
|
20
|
André T, Boni C, Navarro M, et al:
Improved overall survival with oxaliplatin, fluorouracil, and
leucovorin as adjuvant treatment in stage II or III colon cancer in
the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009.PubMed/NCBI
|
|
21
|
Wolmark N, Yothers G, O’Connell MJ, et al:
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab
in stage II or III carcinoma of the colon: results of NSABP
Protocol C-08. J Clin Oncol. 27(Suppl 18): abs. LBA4. 2009.
|
|
22
|
Alberts SR, Sargent DJ, Smyrk TC, et al:
Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS
wild-type (WT) patients (pts) with resected stage III colon cancer
(CC): results from NCCTG Intergroup Phase III Trial NO 147. J Clin
Oncol. 28(Suppl 18): abs. CRA3507. 2010.
|
|
23
|
Goldberg RM, Sargent DJ, Thibodeau SN, et
al: Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients
(pts) with KRAS mutant (m) resected stage III colon cancer (CC):
NCCTG Intergroup Phase III Trial N0147. J Clin Oncol. 28(Suppl 15):
abs. 3508. 2010.
|
